Jaguar Health, Inc. (JAGX): Net Income
-$53.58M
Year ended 2025-12-31
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$53.58M | n/m | 2026-04-07, From 2025-01-01 |
| 2024-12-31 | -$38.49M | n/m | 2026-04-07, From 2024-01-01 |
| 2023-12-31 | -$41.9K | n/m | 2025-04-15, From 2023-01-01 |
| 2022-12-31 | -$48.4K | n/m | 2025-04-15, From 2022-01-01 |
| 2021-12-31 | -$52.6K | n/m | 2025-04-15, From 2021-01-01 |
| 2020-12-31 | -$33.81M | n/m | 2021-03-31, From 2020-01-01 |
| 2019-12-31 | -$38.54M | n/m | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | -$32.15M | n/m | 2020-04-03, From 2018-01-01 |
| 2017-12-31 | -$21.97M | n/m | 2019-04-10, From 2017-01-01 |
| 2016-12-31 | -$14.73M | n/m | 2018-04-09, From 2016-01-01 |
| 2015-12-31 | -$16.29M | n/m | 2017-02-15, From 2015-01-01 |
| 2014-12-31 | -$8.61M | n/a | 2016-03-29, From 2014-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | -$53.58M | n/m |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | -$99.50M | n/m |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | -$153.94M | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | -$7.49M | n/m |
| Evommune, Inc. (EVMN) | 2025-12-31 | -$68.87M | n/m |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | -$124.02M | n/m |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | -$113.62M | n/m |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | -$377.74M | n/m |
| Precigen, Inc. (PGEN) | 2025-12-31 | -$250.64M | n/m |
Compare JAGX, PRLD, CBIO, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗